Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis

被引:22
作者
Albhaisi, Somaya [1 ]
Sanyal, Arun J. [2 ]
机构
[1] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA
[2] Virginia Commonwealth Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA 23284 USA
关键词
NASH; metabolic syndrome; genes; insulin resistance; lipotoxicity; oxidative stress; inflammation; gut microbiome; FATTY LIVER-DISEASE; FIBROSIS PROGRESSION; SIGNATURE; MECHANISMS; PNPLA3; RISK;
D O I
10.3389/fendo.2021.665987
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease worldwide in the past few decades as a consequence of the global obesity epidemic and is associated with significant morbidity and mortality. NAFLD is closely associated with components of the metabolic syndrome, type 2 diabetes mellitus and cardiovascular disease, suggesting a plausible metabolic mechanistic basis. Metabolic inflexibility is considered a nidus for NAFLD pathogenesis, causing lipotoxicity, mitochondrial dysfunction and cellular stress leading to inflammation, apoptosis and fibrogenesis, thus mediating disease progression into nonalcoholic steatohepatitis (NASH) and ultimately cirrhosis. In this review, we describe they key metabolic drivers that contribute to development of NAFLD and NASH, and we explain how NASH is a metabolic disease. Understanding the metabolic basis of NASH is crucial for the prevention and treatment of this disease.
引用
收藏
页数:12
相关论文
共 132 条
[1]   Non-alcoholic fatty liver disease in lean individuals [J].
Albhaisi, Somaya ;
Chowdhury, Abhijit ;
Sanyal, Arun J. .
JHEP REPORTS, 2019, 1 (04) :329-341
[2]  
Albhaisi Somaya A M, 2021, Clin Liver Dis (Hoboken), V17, P15, DOI 10.1002/cld.1010
[3]   Role of gut microbiota in liver disease [J].
Albhaisi, Somaya A. M. ;
Bajaj, Jasmohan S. ;
Sanyal, Arun J. .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2020, 318 (01) :G84-G98
[4]   Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease [J].
Altajar, Sarah ;
Baffy, Gyorgy .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2020, 8 (04) :414-423
[5]   Sarcopenia: a fate worth challenging [J].
不详 .
LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (03) :183-183
[6]   The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2 [J].
Anstee, Quentin M. ;
Day, Christopher P. .
SEMINARS IN LIVER DISEASE, 2015, 35 (03) :270-290
[7]   Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives [J].
Arab, Juan P. ;
Karpen, Saul J. ;
Dawson, Paul A. ;
Arrese, Marco ;
Trauner, Michael .
HEPATOLOGY, 2017, 65 (01) :350-362
[8]   Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The "Musketeer" in the Spotlight [J].
Ballestri, Stefano ;
Nascimbeni, Fabio ;
Romagnoli, Dante ;
Baldelli, Enrica ;
Targher, Giovanni ;
Lonardo, Amedeo .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (03)
[9]   Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis [J].
Banini, Bubu A. ;
Kumar, Divya P. ;
Cazanave, Sophie ;
Seneshaw, Mulugeta ;
Mirshahi, Faridoddin ;
Santhekadur, Prasanna K. ;
Wang, Liangsu ;
Guan, Hong Ping ;
Oseini, Abdul M. ;
Alonso, Cristina ;
Bedossa, Pierre ;
Koduru, Srinivas V. ;
Min, Hae-Ki ;
Sanyal, Arun J. .
HEPATOLOGY, 2021, 73 (04) :1290-1306
[10]   New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease [J].
Barbara, Mary ;
Scott, Andrea ;
Alkhouri, Naim .
HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (05) :372-381